Research programme: biologics - Huabo Biopharm

Next Previous
Drug Profile

Research programme: biologics - Huabo Biopharm

Alternative Names: HB-005; HB-005db; HB-008; HB-016; HB-017; HB-018

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Huabo Biopharm
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lymphoma
  • Research Breast cancer; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 16 Jan 2018 Early research in Breast cancer in China (Parenteral) (Huabo Biopharm pipeline, January 2018)
  • 16 Jan 2018 Early research in Rheumatoid arthritis in China (Parenteral) (Huabo Biopharm pipeline, January 2018)
  • 16 Jan 2018 Early research in Solid tumours in China (Parenteral) (Huabo Biopharm pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top